By | December 4, 2019, 8:15 pm
Intravenous-to-Subcutaneous Drug Repositioning Market

Market Definition

Drug repositioning (also known as drug repurposing or drug reprofiling) is the application of available drugs for treating conditions different from the original treatment purposes. Drug repositioning is supported by the point that common molecular pathways contribute to many diverse diseases. On the other hand, intravenous to subcutaneous drug repositioning is the technique of positioning therapies that involves infusion by medical professionals as subcutaneous (SC) injectable in prefilled devices that are safe and effective when self-administered by the patient.

Global Intravenous-To-Subcutaneous Drug Repositioning market is estimated to reach $XX Million by 2026; growing at a CAGR of XX% from 2019 to 2026.

Request For Sample PDF Report (Kindly Use Your Bussiness/Corporate Email Id to Get Priority): https://www.esticastresearch.com/report/intravenous-to-subcutaneous-drug-repositioning-market/#request-for-sample

Market Dynamics

IV-to-SC drug repositioning offers many advantages over traditional drug discovery approaches which primarily drive the global market. Then again, it significantly reduces the cost and development time as compared to the traditional therapies, which also propels the market growth. However, lack of awareness regarding these therapies across developing regions may hamper the market from growing. Moreover, an increase in developing research labs and infrastructure for conducting drug repositioning clinical trials is expected to generate numerous growth opportunities for the market in the forthcoming years.

Market Segmentation

The global intravenous-to-subcutaneous drug repositioning market is classified based on technology, product type, and therapeutic sector. Based on technology, the market is sub-segmented into drug formulation, injection site modification, and device innovation. The product type segment can be bifurcated into device and drug. The device analysis includes wearable SC injectors and wearable SC infusors), while the drug analysis is given as (antibiotics, antiemetics, blood factors, diuretics, Immune Factors, Hematopoietic, Immunoglobulin G, Prostacyclin, Vasodilators, Immunotherapeutics, Remodulin, and others. Furthermore, by the therapeutic sector, the market is divided into edema, cardiology, hematology, blood factors, pulmonary arterial hypertension, and oncology.

Regional Analysis

Based on geography, the global intravenous-to-subcutaneous drug repositioning market is divided into North America, Asia-Pacific, Europe, South America, and Middle East & Africa. North America is further divided between the U.S., Canada, and Mexico. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

Competitive Players

Some of the key players profiled in the intravenous-to-subcutaneous drug repositioning industry include Baxalta, United Therapeutics, SteadyMed Therapeutics, and CSL Behring among others.

Any Inquiry Related Report Customization Click Here @ https://www.esticastresearch.com/report/intravenous-to-subcutaneous-drug-repositioning-market/#customization

Intravenous-to-Subcutaneous Drug Repositioning Market Key Segments:

By Technology

  • Drug Formulation
  • Injection Site Modification
  • Device Innovation

By Product

  • Devices
    • Wearable SC Injectors
    • Wearable SC Infusors
  • Drugs
    • Blood Factors
    • Diuretics
    • Immunoglobulin G
    • Antibiotics
    • Immunotherapeutics
    • Antiemetics
    • Hematopoietics
    • Immune Factors
    • Prostacyclin
    • Remodulin
    • Vasodilators
    • Others

By Therapeutic Sector

  • Cardiology
  • Edema
  • Pulmonary Arterial Hypertension
  • Hematology
  • Blood Factors
  • Oncology 

By Geography

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • K
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • GCC Countries
    • Egypt
    • South Africa
    • Rest of Middle East & Africa

Key Global Intravenous-to-Subcutaneous Drug Repositioning Industry Players

  • Baxalta
  • SteadyMed Therapeutics
  • United Therapeutics
  • CSL Behring

Intravenous-to-Subcutaneous Drug Repositioning Market By Product (Device Analysis and Drug Product Analysis), By Therapeutic Sector (Cardiology, Edema, Pulmonary Arterial Hypertension, Hematology, Blood Factors, and Oncology), By Technology (Drug Formulation, Injection Site Modification, and Device Innovation), Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2018-2026
Buy Now Full report Copy : https://www.esticastresearch.com/report/intravenous-to-subcutaneous-drug-repositioning-market/

What Report Provides

  • Full in-depth analysis of the parent Industry
  • Important changes in market and its dynamics
  • Segmentation details of the market
  • Former, on-going, and projected market analysis in terms of volume and value
  • Assessment of niche industry developments
  • Market share analysis
  • Key strategies of major players
  • Emerging segments and regional growth potential